Ublituximab-xiiy

(Briumvi®)

Ublituximab-xiiy

Latest News

loading GIF

Drug updated on 4/18/2024

Dosage FormInjection (intravenous; 150 mg/6 mL single-dose vials)
Drug ClassCD20-directed cytolytic antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Ublituximab-xiiy (Briumvi) is indicated for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
  • Two studies compared Briumvi's safety and effectiveness to other disease-modifying therapies (DMTs).
  • It was among the three most efficacious treatments for reducing the annualized relapse rate when compared with a placebo. Additionally, it demonstrated significant efficacy in controlling MRI-detected lesions.
  • Compared to other monoclonal antibody therapies such as ocrelizumab, alemtuzumab, and ofatumumab used for treating RMS, ublituximab shows competitive efficacy, particularly in managing the annualized relapse rates.
  • A study that included data from two randomized controlled trials showed that Briumvi significantly reduced T1 and T2 lesions on MRI scans at week 96 post-initiation when compared with teriflunomide.
  • While specific population types or subgroup considerations are not detailed within these studies, based on its wide-ranging efficacy across different measured outcomes like ARR reduction and lesion activity control on MRIs, it can be inferred that ublituximab may be broadly effective for adults suffering from various forms of MS.

Product Monograph / Prescribing Information

Document TitleYearSource
Briumvi (ublituximab-xiiy) Prescribing Information. 2022TG Therapeutics, Inc., Morrisville, NC

Systematic Reviews / Meta-Analyses